PMID- 19826823
OWN - NLM
STAT- MEDLINE
DCOM- 20100302
LR  - 20211020
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 30
IP  - 3
DP  - 2010 Jan
TI  - Scoring evaluation for histopathological features of synovium in patients with 
      rheumatoid arthritis during anti-tumor necrosis factor therapy.
PG  - 409-13
LID - 10.1007/s00296-009-1158-2 [doi]
AB  - The present study was performed to evaluate the synovium in patients with 
      rheumatoid arthritis (RA) treated with anti-tumor necrosis factor alpha agents 
      (anti-TNFalpha). Synovial tissue specimens were obtained during total knee 
      arthroplasty (TKA) from 42 RA patients (12 men, 30 women). Twenty-one RA patients 
      were given anti-TNFalpha agents (infliximab, n = 12; etanercept, n = 9), while 
      the remaining 21 RA patients were given no such agents.The histopathological 
      findings were compared between specimens from these groups using the histological 
      scoring system reported by Rooney, which consists of six items:degree of synovial 
      hyperplasia, fibrosis, number of blood vessels, perivascular lymphocyte 
      infiltration, focal aggregates of lymphocytes, and diffuse infiltrates of 
      lymphocytes.Clinical laboratory data including C-reactive protein(CRP), matrix 
      metalloproteinase-3 (MMP-3), and disease activity scores including a 28-joint 
      count (DAS28), disease duration, methotrexate (MTX) dose, and glucocorticoid dose 
      were also assessed before surgery. There were no significant differences in total 
      score between anti-TNFalpha and no anti-TNFalpha groups. However, significant 
      differences were observed in scores of synoviocyte hyperplasia and perivascular 
      infiltrates of lymphocytes between the groups. These results suggested that these 
      agents have a suppressive effect on cell proliferation in the lining layer and on 
      perivascular lymphocyte infiltration. However, further studies are necessary to 
      elucidate the mechanisms of these effects.
FAU - Yamanaka, Hajime
AU  - Yamanaka H
AD  - Department of Orthopaedic Surgery, National Hospital Organization, Shimoshizu 
      Hospital, 934-5 Shikawatashi, Yotsukaido 284-0003, Japan. ici05323@m7.gyao.ne.jp
FAU - Goto, Ken-ichiro
AU  - Goto K
FAU - Miyamoto, Kazutoshi
AU  - Miyamoto K
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Glucocorticoids)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - B72HH48FLU (Infliximab)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal/*pharmacology/therapeutic use
MH  - Antirheumatic Agents/pharmacology/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/*pathology/physiopathology
MH  - Arthroplasty, Replacement, Knee
MH  - Biomarkers/analysis/metabolism
MH  - Biopsy
MH  - C-Reactive Protein/analysis/metabolism
MH  - Cell Proliferation/drug effects
MH  - Chemotaxis, Leukocyte/drug effects/immunology
MH  - Female
MH  - Glucocorticoids/administration & dosage
MH  - Humans
MH  - Hyperplasia/drug therapy/physiopathology/prevention & control
MH  - Infliximab
MH  - Knee Joint/*drug effects/*pathology/physiopathology
MH  - Lymphocyte Activation/drug effects/immunology
MH  - Lymphocytes/drug effects/immunology/pathology
MH  - Male
MH  - Matrix Metalloproteinase 3/analysis/metabolism
MH  - Methotrexate/administration & dosage
MH  - Middle Aged
MH  - Neovascularization, Pathologic/drug therapy/pathology/physiopathology
MH  - Outcome Assessment, Health Care/methods
MH  - Synovial Membrane/drug effects/pathology/physiopathology
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
EDAT- 2009/10/15 06:00
MHDA- 2010/03/03 06:00
CRDT- 2009/10/15 06:00
PHST- 2009/07/20 00:00 [received]
PHST- 2009/09/20 00:00 [accepted]
PHST- 2009/10/15 06:00 [entrez]
PHST- 2009/10/15 06:00 [pubmed]
PHST- 2010/03/03 06:00 [medline]
AID - 10.1007/s00296-009-1158-2 [doi]
PST - ppublish
SO  - Rheumatol Int. 2010 Jan;30(3):409-13. doi: 10.1007/s00296-009-1158-2.